Katz Daniela, Palmerini Emanuela, Pollack Seth M
From the Institute of Oncology, Assaf Harofeh Medical Center, Zrifin, Beer Yaakov, Israel; Medical Oncology, Istituto Ortopedico Rizzoli, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University, Bologna, Italy; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.
Am Soc Clin Oncol Educ Book. 2018 May 23;38:925-938. doi: 10.1200/EDBK_205423.
Sarcomas are a diverse group of cancers with mesenchymal origin. Although sarcomas comprise less than 1% of cancers, there are more than 50 different subtypes that are quite different from one another in terms of both their biology and clinical behavior. Historically, the need for adequate patient numbers in clinical trials has pushed sarcoma researchers to lump these very different malignancies together and treat the patients using a "one-size-fits-all" approach. However, with improvements in our scientific understanding, we are finally ready for a histology-tailored therapeutic approach to these complex diseases. In this review, we discuss key advances in our understanding of the biology underlying selected sarcoma subtypes and how targeting these subtypes is relevant therapeutically with respect to both molecularly targeted agents as well as immunotherapy.
肉瘤是一组起源于间充质的多样化癌症。尽管肉瘤在所有癌症中占比不到1%,但有50多种不同的亚型,它们在生物学特性和临床行为方面都有很大差异。从历史上看,由于临床试验需要足够数量的患者,肉瘤研究人员不得不将这些截然不同的恶性肿瘤归为一类,并采用“一刀切”的方法治疗患者。然而,随着我们科学认识的提高,我们终于准备好针对这些复杂疾病采用组织学定制的治疗方法。在这篇综述中,我们讨论了对选定肉瘤亚型生物学基础认识的关键进展,以及针对这些亚型在分子靶向药物和免疫治疗方面的治疗相关性。